Neuroimaging Data in Bipolar Disorder: An Updated View
B. Dell’Osso,C. Dobrea,M. Palazzo,L. Cremaschi,C. Arici,B. Benatti,A. Altamura
DOI: https://doi.org/10.5772/24566
2012-05-16
Abstract:BD is a prevalent mood disorder, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed (Altamura et al., 2011a). Intense emotional states that occur in BD comprise manic, hypomanic, mixed or depressive episodes. According to the Diagnostic and Statistical Manual of Mental Disorders, IVth edition, text revision (DSMIV–TR; American Psychiatric Association, 2000), BD spectrum ranges from cyclothymia to Bipolar I, Bipolar II Disorder and Not Otherwise Specified (NOS) forms. BD can also be conceptualized as a gradual change in mood scale, which ranges from severe depression to severe mania with an intermediate euthymic state or balanced mood. Dysthymia is a chronic state of mild low mood occurring for a minimum of two years. At the other end of the scale there is hypomania and severe mania. An alternative and broader dimensional approach conceptualizes BD as a continuum, between unipolar depression, schizoaffective disorder (which is considered by some authors a subcategory of BD) and schizophrenia. This theory may be supported from a clinical point of view by the fact that, sometimes, during severe manic, mixed or depressive episodes, bipolar patients experience psychotic symptoms, such as hallucinations or delusions. It is also supported by the presence of morphometric alterations of frequent observation among major psychoses, such as enlarged ventricles and white matter volume reductions in the left and temporoparietal regions (Czobor et al., 2007). In BD, symptomatic states are frequently associated with poor working functioning and social impairment. Bipolar patients, moreover, have higher suicide rates than the general population and among the highest of psychiatric patients. In a recent study on factors predicting suicide in BD, white race, family history of suicide, and previous cocaine abuse were considered predictive of suicidal behaviour (Cassidy, 2011). Usually BD develops in early adulthood/late teens, with an age of onset ranging from 15 to 50 years (Cassano et al., 2006). International treatment guidelines for BD recommend the use of mood stabilizers either in monotherapy or in association as the gold standard in both acute and long-term therapy. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability (Altamura et al., 2011b). Beyond the